Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation

Ching Yih Lin, Yu Feng Tian, Li Ching Wu, Li Tzong Chen, Li Ching Lin, Chung Hsi Hsing, Sung Wei Lee, Ming Jen Sheu, Hao Hsien Lee, Yu Hui Wang, Yow Ling Shiue, Wen Ren Wu, Hsuan Ying Huang, Han Ping Hsu, Chien Feng Li, Shang Hung Chen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT. Methods: Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival. Results: Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced posttreatment tumour status (T3, T4, p

Original languageEnglish
Pages (from-to)687-692
Number of pages6
JournalJournal of Clinical Pathology
Volume65
Issue number8
DOIs
Publication statusPublished - Aug 2012
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation'. Together they form a unique fingerprint.

  • Cite this

    Lin, C. Y., Tian, Y. F., Wu, L. C., Chen, L. T., Lin, L. C., Hsing, C. H., Lee, S. W., Sheu, M. J., Lee, H. H., Wang, Y. H., Shiue, Y. L., Wu, W. R., Huang, H. Y., Hsu, H. P., Li, C. F., & Chen, S. H. (2012). Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation. Journal of Clinical Pathology, 65(8), 687-692. https://doi.org/10.1136/jclinpath-2012-200786